2.84
5.58%
0.15
After Hours:
2.84
Vistagen Therapeutics Inc Stock (VTGN) Latest News
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Great Point Partners LLC - MarketBeat
Analyzing Vistagen Therapeutics (NASDAQ:VTGN) and Daré Bioscience (NASDAQ:DARE) - Defense World
Anxiety drug trials keep Stifel optimistic on VistaGen stock's upside potential - Investing.com Canada
Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.1% in October - Defense World
Great Point Partners LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com
Citadel Advisors LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com
Vistagen Therapeutics adds SKDK, GCI Health alum Michelle Peters Wellington - MM+M Online
Vistagen CEO to Present at Stifel 2024 Healthcare Conference | VTGN Stock News - StockTitan
Vistagen to Present at the Stifel 2024 Healthcare Conference - Business Wire
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Q1 Earnings Estimate for VTGN Issued By William Blair - MarketBeat
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates - MSN
Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlight - GuruFocus.com
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... - Yahoo Finance
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... By GuruFocus - Investing.com Canada
Vistagen Therapeutics Reports Increased R&D Expenses - TipRanks
Vistagen Therapeutics Inc Reports Q2 2025 Revenue of $183,000, M - GuruFocus.com
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update - Business Wire
Vistagen reports Q2 EPS (42c), consensus (39c) - TipRanks
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect - GuruFocus.com
Vistagen to Present at the 2024 Neuroscience Education Institute Congress - Business Wire
Vistagen to Present Breakthrough SAD Treatment Data at 2024 NEI Congress | VTGN Stock News - StockTitan
Vistagen Therapeutics (VTGN) Scheduled to Post Earnings on Thursday - MarketBeat
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 - sharewise
VTGN (Vistagen Therapeutics) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
Generalized Anxiety Disorder Pipeline 2024: Clinical Trials - openPR
Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder - Seeking Alpha
VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know - MSN
Mental Disorder Treatment Market Global Industry Forecast - openPR
Vistagen, The Goldie Hawn Foundation, and MindUP students Rings the Nasdaq Stock Market Closing Bell on World Mental Health Day - Nasdaq
Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges - Yahoo Finance UK
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day - sharewise
Great Point Partners LLC Has $5.32 Million Stock Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Vistagen enrols first subject in Phase III trial of social anxiety disorder drug - Yahoo Finance
Vistagen advances phase 3 trial for social anxiety treatment By Investing.com - Investing.com Australia
Vistagen advances phase 3 trial for social anxiety treatment - Investing.com
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - StockTitan
All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy - Benzinga
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy - Yahoo Finance
Mental Disorder Treatment Market Expected to Expand at a Steady - openPR
Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth - Yahoo Finance
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below Fifty Day Moving Average of $3.52 - MarketBeat
Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Below 50 Day Moving Average of $3.52 - Defense World
Mental Disorder Treatment Market Detailed In New Research - openPR
Vistagen shareholders approve board nominees and executive pay By Investing.com - Investing.com Canada
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):